Endocrine disorders

Adjunct to levodopa (with a decarboxylase inhibitor) in Parkinson’s disease

Inhibition/suppression of lactation

Parkinson’s disease: 2–6 mg daily

Hyperprolactinaemic disorders: 0.25–2 mg weekly

Inhibition of lactation: single 1 mg dose during first day post partum

Suppression of lactation: 0.25 mg twice a day for 2 days

Molecular weight :451.6

%Protein binding :41–42

%Excreted unchanged in urine : 2–3

Volume of distribution (L/kg) :No data

half-life – normal/ESRD (hrs) :63–68 (healthy individuals), 79–115 (hyperprolactinaemic individuals)/Unchanged

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

CAPD :Dialysed. Dose as in normal renal function

HD :Dialysed. Dose as in normal renal function

HDF/high flux :Dialysed. Dose as in normal renal function

CAV/VVHD :Dialysed. Dose as in normal renal function

Potentially hazardous interactions with other drugs

None known

–

Oral

–

–

18% of radiolabelled dose is excreted as inactive metabolites in urine72% of dose is excreted in faeces